Karyopharm Therapeutics | KPTI - DEBITO





DEBITO Cambiamento Data
AbbVie USD 67.5B 67.5B 2025-12
Abbott USD 34.05B 20.19B 2026-03
Amgen USD 54.6B 17M 2025-12
AstraZeneca USD 33.92B 4.3B 2026-03
BioCryst Pharmaceuticals USD 828.6M 510K 2024-12
Bristol-Myers Squibb USD 47.14B 3.9B 2025-12
Eli Lilly USD 42.5B 3.6M 2025-12
Enanta Pharmaceuticals USD 1.35M 0 2024-12
GlaxoSmithKline GBP 19.06B 1.34B 2026-03
Incyte USD 39.43M 982K 2026-03
J&J USD 54.99B 7.05B 2026-03
Karyopharm Therapeutics USD 299.23M 35.14M 2025-12
MacroGenics USD 36.51M 500K 2026-03
Merck USD 49.34B 7.97B 2025-12
Nektar Therapeutics USD 0 0 2022-06
Novartis USD 47B 11.62B 2026-03
Novartis USD 47B 14.98B 2026-03
Pfizer USD 63.73B 231M 2026-03
Regeneron Pharmaceuticals USD 2.71B 300K 2026-03
Roche Holding CHF 33.03B 1.41B 2025-06
Sangamo BioSciences USD 0 0 2022-06
Takeda JPY 4.85T 208B 2025-12
Tectonic Therapeutic USD 876K 115K 2024-12
TG Therapeutics USD 253.71M 8.37M 2025-12
Ultragenyx Pharmaceutical USD 36M 2.17M 2025-12
Xencor USD 187.75M 118.48M 2025-12